|
Market Closed -
OTC Markets
15:12:15 2025-07-28 EDT
|
5-day change | 1st Jan Change | ||
| 30.92 USD | +24.45% |
|
-.--% | - |
| 09-18 | EU Medicines Agency Panel Issues Positive Opinion on Gedeon Richter's Arthritis Drug | MT |
| 08-11 | Gedeon Richter PLC, Q2 2026 Earnings Call, Aug 07, 2026 |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 65.18B | 31.67% | 41.84% | 106.69% | 22.77% | 1.2x | |
| 94.19B | 28.46% | 32.23% | 31.68% | 13.82% | 0.84x | |
| 61.16B | 6.91% | 38.79% | 64,669.09% | 13.22% | 2.44x | |
| 65.01B | 28.08% | 41.19% | 45.52% | 17.73% | 1.07x | |
| 77.58B | 20.94% | 35.49% | 47.65% | 15.43% | 0.66x | |
| 56.67B | 24.64% | 38.62% | 38.4% | 16.33% | 1.02x | |
| 58.74B | 17.41% | 31.46% | 31.99% | 13.12% | 1.2x | |
| 36.75B | 20.98% | 44.09% | 162.88% | 12.98% | 2.13x | |
| 29.44B | 28.9% | 44.81% | 48.87% | 17.34% | 1.08x | |
| 48.59B | 33.14% | 41.3% | 60.7% | 20.31% | 0.69x | |
| 62.58B | 12.42% | 35.11% | 21.07% | 8.73% | 1.79x | |
| 12B | 32.94% | 43.85% | 27.07% | 16.41% | -1.21x | |
| 48.19B | 14.64% | 30.37% | 72.08% | 7.72% | 1.83x | |
| 403B | 1.18% | 1.6% | - | 6.16% | 0.37x | |
| 51.22B | 17.91% | 27.85% | 10.5% | 6.02% | 0.81x | |
| 43.97B | 17.5% | 29.95% | 46.39% | 9.48% | 1.28x | |
| 1.94B | -145.16% | -158.13% | -28.87% | -21.31% | 2.03x | |
| 14.34B | 31.41% | 34.05% | 16.13% | 12.48% | -1.09x | |
| 24.78B | 12.36% | 17.06% | 12.4% | 5.06% | 1.51x | |
| Average | 66.09B | 12.44% | 23.77% | 3,634.46% | 11.25% | 1.03x | |
| Weighted average by Cap. | 67.76B | 20.89% | 33.84% | 6,364.72% | 15.13% | 1.16x |
- Stock Market
- Stocks
- RICHTER Stock
- GEDSF Stock
- Sector Gedeon Richter
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
